[Changes in fluorosis clinical manifestations under treatment and during post-contact period].
The article covers results of health state monitoring in patients with fluorosis stages I and II, who remain or continue contact with fluor and its compounds. The author evaluated treatment efficiency for fluorosis patients and risk group members, demonstrated efficiency of therapy designed with consideration of biologic rhythms in various body systems, clinical manifestations and the disease pathogenesis.
Odinokaia
V A
VA
D000328:Adult; D001847:Bone Diseases / Q000139:chemically induced / Q000453:epidemiology / Q000473:pathology; D002908:Chronic Disease; D005461:Fluorine / Q000009:adverse effects* / Q000506:poisoning; D006801:Humans; D008297:Male; D008875:Middle Aged; D009784:Occupational Diseases / Q000139:chemically induced* / Q000453:epidemiology*; D012720:Severity of Illness Index
D005461:Fluorine